Welcome to our dedicated page for Barrick Mining Corporation news (Ticker: B), a resource for investors and traders seeking the latest updates and insights on Barrick Mining Corporation stock.
The Barrick Mining Corporation (NYSE: B, TSX: ABX) news page on Stock Titan provides a focused view of company announcements and market-facing disclosures for one of the world’s largest gold miners. Barrick’s news flow reflects its role as a major producer of gold and copper, with operations and projects across the Americas, Africa, the Middle East, and Asia.
Investors following B stock can use this page to track key corporate updates that shape the company’s outlook. These include notices about upcoming earnings releases and webcasts, such as the announcement that Barrick will report its full year and fourth quarter 2025 results on February 5, 2026, with a live webcast and analyst question-and-answer session. Such events offer insight into production performance, costs, project progress, and capital allocation decisions.
Alongside earnings-related news, Barrick’s regulatory communications often appear in the form of press releases furnished with its Form 6-K filings. These may cover quarterly results, comparative unaudited financial statements prepared in accordance with International Financial Reporting Standards, management’s discussion and analysis, and capital management actions such as share buyback programs.
By reviewing the Barrick Mining Corporation news feed, readers can monitor how the company reports on its gold and copper production profile, reserve base, and key projects like the Lumwana expansion and the Reko Diq copper and gold development. Bookmark this page to quickly access the latest Barrick announcements, scheduled results dates, and other official disclosures that inform analysis of the B stock.
BioArctic (Nasdaq: B) partner Eisai announced that Leqembi (lecanemab) has been included in China’s new Commercial Insurance Innovative Drug List, effective January 1, 2026. The list enables commercial insurers to negotiate coverage products for listed innovative medicines, aiming to narrow the gap with the National Reimbursement Drug List.
Eisai launched Leqembi in China in June 2024 and estimates 17 million people had MCI or mild dementia due to Alzheimer’s in China in 2024. Leqembi was originally developed by BioArctic and is commercialized in China by Eisai; BioArctic retains Nordic commercialization rights and is preparing joint commercialization with Eisai in that region.
Cereno Scientific (B) announced that the U.S. FDA cleared initiation of its global Phase IIb trial of lead candidate CS1 for pulmonary arterial hypertension (PAH).
The randomized, double-blind, placebo-controlled, dose-finding study will enroll ~126 patients across ~65 sites in 10–12 countries, run 60 weeks total, and evaluate PVR by right-heart catheterization and 6-minute walk distance at Week 36. CS1 holds Orphan Drug and Fast Track designations. First patient in is planned for Q2 2026, with top-line data anticipated around Q4 2028 subject to enrollment timelines.
BioArctic partner Eisai (NYSE:B) presented CTAD 2025 data showing continued lecanemab (Leqembi) treatment may delay Alzheimer’s progression by up to 8.3 years in a low‑amyloid subgroup who started treatment early. Analysis used Clarity AD OLE and ADNI natural‑history data to estimate 10‑year time savings by CDR‑SB, with overall delays of 2.5–3.5 years vs untreated and larger gains in low‑amyloid patients.
Separately, a subcutaneous autoinjector (SC‑AI) approved for maintenance in the US (Aug 2025) showed bioequivalent exposure to IV dosing (exposure ratio 104%, 90% CI 99.1%–109%), low systemic infusion reactions, ADA 1.4%, and predicted ARIA‑E rates of 12.4% (30.9% in ApoE4 homozygotes). sBLA for initiation completed Nov 2025; Japan SC submission Nov 2025.
ETQ (NYSE:B) launched ETQ Reliance Go on December 3, 2025, a cloud-native electronic quality management system (EQMS) for small- to mid-sized manufacturers.
The SaaS offering provides a self-service implementation path, simple licensing-only pricing, built-in best-practice templates and on-demand training to enable administrators to deploy without IT or vendor services. Key features include AWS-based infrastructure, preconfigured processes (document control, training, audit, nonconformance), modular apps and automated performance tracking. ETQ Reliance Go is available immediately.
B (Barrick) completed the divestiture of its interests in the Tongon gold mine and certain exploration properties in Côte d’Ivoire to Atlantic Group for total consideration of up to $305 million.
The consideration comprises $192 million in cash (which includes a $23 million shareholder loan repayment payable within six months of closing) and contingent cash payments up to $113 million tied to the price of gold over 2.5 years and resource conversions over 5 years.
Barrick (NYSE:B) announced its Board has authorized management to explore an initial public offering (IPO) of a subsidiary ("NewCo") that would hold Barrick’s North American gold assets.
NewCo would be anchored by Barrick’s joint venture interests in Nevada Gold Mines and Pueblo Viejo, plus the wholly owned Fourmile discovery in Nevada. The IPO is contemplated as a listing of a small minority interest while Barrick intends to retain a significant controlling majority. The Board authorized exploration through early 2026 and the company will update progress at its Full Year 2025 Results in February 2026. Any IPO decision remains subject to Board approval, customary requirements, and market conditions.
B (Barrick) completed the divestiture of the Hemlo Gold Mine in Canada to Carcetti Capital Corp., which will be renamed Hemlo Mining Corp (HMC), for total consideration of up to $1.09 billion.
Transaction proceeds included $875 million in cash received on closing, $50 million in HMC shares received on closing, and a production and tiered gold price-linked cash payment structure of up to $165 million payable over a five-year term starting in January 2027. The company acknowledged cooperation from the Biigtigong Nishnaabeg and Netmizaaggamig Nishnaabeg First Nations.
Barrick (NYSE:B) announced on November 26, 2025 that Ben van Beurden has stepped down as a director and as Lead Independent Director. Loreto Silva, an existing non-executive director, will succeed him as Lead Independent Director. The chairman said the board is focused on delivering long-term value and described the company as having industry-leading assets and a strengthened leadership team aligned on strategic priorities.
Barrick (NYSE:B) announced on November 24, 2025 that it has reached an agreement with the Government of the Republic of Mali to end disputes over the Loulo and Gounkoto mines.
Under the agreement, all charges against Barrick, its affiliates and employees will be dropped, the legal steps to secure the release of four detained Barrick employees will be taken, and the provisional administration of the Loulo-Gounkoto complex will be terminated, returning operational control to Barrick. Barrick subsidiaries will also withdraw ICSID arbitration claims, enabling a constructive path forward.
Crawford & Company (NYSE: CRD-A and CRD-B) announced a leadership transition: CEO Rohit Verma will step down effective December 31, 2025, and CFO W. Bruce Swain Jr. will become interim president & CEO and board member effective January 1, 2026. Holly Boudreau will succeed Swain as CFO effective January 1, 2026. Swain brings more than 30 years at Crawford and will focus on executing strategic plans and empowering employees. Verma served as CEO since May 2020 and joined Crawford in 2017. The company describes the transition as occurring from a position of financial strength with a global leadership team in place.